Cover Story
The NCI-60, a panel of 60 cancer cell lines that have become the Rosetta Stone for the development of anticancer drugs, may be entering its twilight years as NCI develops new, and more expansive, patient-derived xenografts, or PDX models.
In Brief
Funding Opportunities
Drugs & Targets
Trending Stories
- Leading a Comprehensive Cancer Center—one job or two?
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- “This is our time, and the time is now”—Chapman tells us about Jefferson’s final push for Comprehensive designation
- Call to action: To address Black cancer disparities, focus on research prioritization and clinical studies inclusion
Minority Cancer Awareness Week - Tobacco in the tabloids: How the Weekly World News covered smoking for laughs—and the National Enquirer wouldn’t cover it at all